Drug Trial Radar · NCT07318688
Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Jan 29, 2026
Primary completion
Mar 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Hope Medicine (Nanjing) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension
Conditions
- Endometriosis
Interventions
HMI-115Drug
HMI-115 is human monoclonal antibody (120mg/vail)
PlaceboDrug
Placebo (0mg/vail)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline (CFB) in dysmenorrhea (DYS) measured by Numeric Rating Scale (NRS) at Week 12Time frame: week 12
- CFB in non-menstrual pelvic pain (NMPP) measured by NRS at Week 12Time frame: week 12
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Nanjing Women and children's healthcare hospital
Nanning, Jiangsu, China · Not yet recruiting
Second Affiliated Hospital of Soochow University
Suzhu, Jiangsu, China · Recruiting
The International Peace Maternity and Child Health Hospital of the China Welfare Institute
Shanghai, Shanghai Municipality, China · Not yet recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.